Transforming Discovery of Therapeutics and Materials February 24, 2022 Fourth Quarter and Full-Year 2021 Supplemental Slides Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding the potential advant ...

Financial Data and Key Metrics Changes - Total revenue for 2021 was $137.9 million, a 28% increase over the prior year, with Q4 software revenue reaching $38.6 million, a 55% increase compared to Q4 2020 [7][13] - Operating expenses for Q4 2021 were $48.9 million, up from $35.6 million in Q4 2020, reflecting increased investment in R&D [13] - The net loss for 2021 was $101.2 million compared to a loss of $26.6 million in 2020 [15] Business Line Data and Key Metrics Changes - Software revenue for the full year was $113.2 million, up 22% over 2020, driven by strong growth in both life sciences and material sciences [14] - Drug discovery revenue for 2021 was $24.7 million, compared to $15.6 million in 2020, primarily due to revenue recognized from collaboration with BMS [15] Market Data and Key Metrics Changes - Total software annual contract value (ACV) reached $112.1 million in 2021, a 22% increase year-over-year [16] - The number of customers with ACV over $1 million was 15, with total ACV in this category increasing to $40.2 million in 2021, up from $35.5 million in 2020 [16] Company Strategy and Development Direction - The company aims for ACV growth of over 20% in 2023 and expects drug discovery revenue of at least $100 million in 2023, excluding potential revenue from lead internal programs [20] - The acquisition of XTAL BioStructures is intended to enhance structural biology capabilities and support drug discovery efforts [8][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2022, expecting total annual revenue to be in the range of $161 million to $181 million, corresponding to 17% to 31% growth over 2021 [17] - The company anticipates continued strong growth in software revenue, with expectations for Q1 2022 software revenue to range from $28 million to $30 million [18] Other Important Information - The company established operations in Seoul, South Korea, and expanded operations in Hyderabad, India, to enhance competitive positioning [9] - Joel Lebowitz announced his retirement at the end of February 2022, with the company actively searching for his successor [11] Q&A Session Summary Question: What drove the strength in software revenue in Q4? - Management noted that the growth was driven by increased adoption of solutions by existing large customers and the addition of new customers [32] Question: How confident is the company in the drug discovery revenue guidance for 2023? - Management expressed confidence based on a broad portfolio of collaboration programs, with about 20 programs currently in the pipeline [34] Question: What is the status of the IND filing for the MALT1 program? - The company has completed GLP toxicology studies and is in the final planning phase for the IND submission, having interacted with the FDA [36] Question: What drives performance to either side of the software sales guidance for 2022? - Management indicated that performance is influenced by the commitment level of large customers to adopt solutions more extensively [40] Question: How does the company prioritize which programs to add to its pipeline? - The company focuses on targets with preclinical and human evidence, considering the clinical landscape and potential for compelling clinical data [46]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39206 Schrodinger, Inc. (Exact name of Registrant as specified in its Charter) Delaware 95-4284541 (State or other jurisdiction of in ...

Schrödinger, Inc. (NASDAQ:SDGR) Q3 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Ramy Farid – CEO Joel Lebowitz – CFO Karen Akinsanya – Executive Vice President Jaren Madden – Senior Vice President, IR Conference Call Participants Michael Ryskin – Bank of America Gary Nashman – BMO Capital Markets Matt Hewitt – Craig-Hallum Capital Group Gora Gabarachu – BMO Capital Michael Yee – Jefferies Operator Thank you for standing by. Welcome to Schrodinger's conference call to review the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4284541 (State or other jurisdicti ...

Schrödinger, Inc. (CSIQ) Q2 2021 Earnings Conference Call August 12, 2021 8:30 AM ET Company Participants Ramy Farid – President and CEO Tracy Lessor – Executive Director of Corporate Communications Karen Akinsanya – Executive Vice President, Chief Biomedical Scientists, and Head of Discovery R&D Joel Lebowitz – Executive Vice President and CFO Conference Call Participants Michael Yee – Jefferies Michael Ryskin – Bank of America Gary Nashman – BMO Capital Markets David Lebowitz – Morgan Stanley Matt Hewitt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 95-4284541 | | --- | --- | | (State or ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2021 was $32.1 million, representing a 23% increase compared to Q1 2020 [34] - Software revenue reached $26.3 million, reflecting an 11% growth year-over-year [35] - Drug discovery revenue was $5.8 million, up from $2.4 million in Q1 2020, including $2.2 million from a collaboration milestone recognized earlier than anticipated [36][37] - Gross profit was $16.2 million, a 3% increase from the previous year, with software gross margin at 78%, down from 83% [38] - Operating expenses rose to $40.1 million from $27.4 million in Q1 2020, driven by R&D investments and public company infrastructure costs [39] - The company recorded a net loss of approximately $29,000, a significant improvement from a loss of $13.8 million in the prior year [41] - Cash and equivalents at the end of Q1 2021 were $649 million, up from $643.2 million at the end of Q4 2020 [41] Business Line Data and Key Metrics Changes - Software revenue growth was attributed to increased deployment of solutions and new customer growth [35] - Drug discovery revenue included significant contributions from collaborations, particularly with Bristol Myers Squibb [36][37] Market Data and Key Metrics Changes - The company is experiencing a strong financial position, allowing for continued investment in R&D and growth initiatives [16] Company Strategy and Development Direction - The company aims to leverage its computational platform for drug discovery and materials applications, focusing on high-quality molecule identification [9][10] - Strategic collaborations, such as with NVIDIA and AstraZeneca, are intended to enhance platform capabilities and broaden deployment [15][13] - The company is committed to advancing its internal drug discovery pipeline and expanding its software business [16][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to in-person work by Q4 2021 and highlighted the dedication of employees during COVID-19 challenges [17] - The company reaffirmed its full-year revenue guidance, expecting total annual revenue between $124 million and $142 million [42] - Anticipated software revenue growth is expected to be higher in the second half of the year, particularly in Q4 [43] Other Important Information - The company is focused on maintaining its leadership in physics-based computation and machine learning to enhance prediction accuracy [14] - The internal drug discovery pipeline is advancing, with plans for IND submissions in 2022 for several programs [21][32] Q&A Session Summary Question: Software revenue guidance and confidence - Management maintained guidance for software revenue, expecting higher growth in the second half of the year, particularly in Q4 [52][54] Question: MALT1 program and IND submissions - The company plans to move forward with IND studies for the MALT1 program and remains open to potential partnerships [56][57] Question: Software revenue seasonality - Management confirmed that Q1 typically shows stronger software revenue compared to Q2, with expectations for higher growth in the second half of the year [61][62] Question: AstraZeneca collaboration details - The expanded collaboration with AstraZeneca is a significant step, transitioning from a pilot program to broader deployment across their programs [72][73] Question: Cost of constructing internal programs - The estimated cost for external companies to construct similar internal programs is around $30 million to $40 million for software licenses alone [75] Question: Progress on collaborative programs - The company remains confident in advancing collaborative programs through GLP-tox studies and IND enabling studies [80] Question: Pharmaceutical purchasing dynamics - Most contracts are annual, but companies may make incremental decisions throughout the year based on needs [88][89]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4284541 (State or other jurisdiction o ...

SCHRÖDINGER. Transforming Discovery of Therapeutics and Materials March 23, 2021 Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding the potential advantages of our physics-based computational plat ...